Right-Sided Ductal Carcinoma in Situ Before a Second Breast Cancer
This breast cancer diagnosis at a glance
- Subtype
- Invasive Ductal Carcinoma
- Biomarkers
- ER-positive; PR-positive; HER2 1+
- Sex
- female
- Treatment
- surgery, radiation, targeted therapy and endocrine therapy
Treatment course, step by step
- Underwent modified radical mastectomy of the right breast in March 2018.
- Received postoperative radiotherapy.
- Received trastuzumab for 1 year through March 2019.
- Took anastrozole from 2019 until November 2020.
What happened, in summary
This woman had her first documented breast-cancer diagnosis in March 2018, when she underwent a modified radical mastectomy of the right breast. Pathology showed ductal carcinoma in situ, and none of 24 sampled axillary lymph nodes contained cancer. The tumor was estrogen-receptor positive and progesterone-receptor positive, with HER2 reported as 1+.
After surgery, she received radiotherapy and then 1 year of trastuzumab, ending in March 2019. She also began anastrozole in 2019 and stopped it in November 2020.
Later in 2020, she developed a separate invasive cancer in the left breast. That later cancer followed a different course and ultimately became metastatic, so its treatment and outcome are kept in a separate cancer-level record rather than being attributed to the earlier right-sided ductal carcinoma in situ.
Where this story comes from
This is a lay summary of an account first published by PMC / PubMed Central. Read the original in full
How we source and attribute stories Accuracy and limitations
Collections this story belongs to
- ER Positive Breast Cancer 242 stories
- Anastrozole for Breast Cancer 71 stories
These are lay summaries of published cancer stories, for information only. No two cancers behave the same way, and nothing here predicts your own diagnosis or replaces advice from your oncology team. Read the full disclaimer